The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Pfizer made one thing clear this week: It's officially back in the obesity race.

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a ...

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...

With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, "Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets ...

Feb 3(Reuters) - Pfizer on Tuesday reported fourth-quarter earnings above Wall Street estimates, as sustained demand for ...

New weight loss drug by Pfizer shows promising results in trial - Pfizer acquired the drug’s developer following a bidding ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...